Maternal and Infant Factors Predicting Disease Progression in Human Immunodeficiency Virus Type 1-Infected Infants
- 1 January 2000
- journal article
- research article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 105 (1) , e8
- https://doi.org/10.1542/peds.105.1.e8
Abstract
Background. Infants with perinatally acquired human immunodeficiency virus type 1 (HIV-1) infection have widely variable courses. Previous studies showed that a number of maternal and infant factors, when analyzed separately, are associated with infant HIV-1 disease progression. In this study, clincal, virologic, and immunologic characteristics in the mothers and infants were examined together to determine the predictors of disease progression by 18 months of age and the associations with rapid progression during the first 6 months of life. Methods. One hundred twenty-two HIV-1-infected women whose infants were HIV-1 infected were identified from the Women and Infants Transmission Study (WITS) cohort. WITS is a longitudinal natural history study of perinatal HIV-1 infection carried out in 6 sites in the continental United States and in Puerto Rico. The women were enrolled during pregnancy and their infants were enrolled at the time of delivery and followed prospectively by a standardized protocol. Virologic and immunologic studies were performed in laboratories certified by National Institutes of Health-sponsored quality assurance programs. Maternal factors in pregnancy were used as potential predictors of infant disease progression (progression to Centers for Disease Control and Prevention [CDC] Clinical Class C disease or death by 18 months of age) or as correlates of progression at Results. Progression by 18 months of age occurred in 32% of infants and by 6 months of age in 15%. Maternal characteristics that, by univariate analysis, were significant predictors of infant disease progression by 18 months of age were elevated viral load, depressed CD4+%, and depressed vitamin A. CD8+%, CD8+ activation markers, zidovudine (ZDV) use, hard drug use, and gestational age at delivery were not. When examined in a combined multivariate analysis of maternal characteristics, only vitamin A concentration independently predicted infant progression. Infant characteristics during the first 6 months of life that, by univariate analysis, were associated with disease progression included elevated mean viral load at 1 to 6 months of age, depressed CD4+%, CDC Clinical Disease Category B, and growth delay. Early HIV-1 culture positivity (+%, CD8+ activation markers, and ZDV use during the first month of life did not predict progression. Multivariate analysis of infant characteristics showed that the only independent predictors were progression to CDC Category B by 6 months of age (odds ratio [OR], 5.80) and mean viral load from 1 to 6 months of age (OR, 1.99). The final combined maternal and infant analysis included the significant maternal and infant characteristics in a multivariate analysis. It showed that factors independently predicting infant progression by 18 months of age were progression to CDC Category B by 6 months of age (OR, 5.80) and elevated mean HIV-1 RNA copy number at 1 to 6 months of age (OR, 1.99). The characteristics associated with rapid progression to CDC Category C disease or death by 6 months of age were also examined. The only maternal characteristic associated with progression by 6 months in multivariate analysis was low maternal CD4+%. The infant characteristics associated with progression by 6 months of age in multivariate analysis were depressed mean CD4+% from birth through 2 months and the presence of lymphadenopathy, hepatomegaly, or splenomegaly by 3 months. Infant ZDV use was not assocciated with rapid progression. Conclusion. The strongest predictors of progression by 18 months are the presence of moderate clinical symptoms and elevated RNA copy number in the infants in the first 6 months of life. In contrast, progression by 6 months is associated with maternal and infant immune suppression, and the presence of infant clinical symptoms. The difference suggests that the key pathogenetic mechanisms responsible for progression may vary with age. These observations help provide direction for future pathogenesis research and assist in clinical care.Keywords
This publication has 24 references indexed in Scilit:
- Morbidity and Mortality in European Children Vertically Infected by HIV-1JAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- Development of a prognosis-based clinical staging system for infants infected with human immunodeficiency virusThe Journal of Pediatrics, 1996
- Prospective study of human immunodeficiency virus 1-related disease among 512 infants born to infected women in New York CityThe Pediatric Infectious Disease Journal, 1996
- Dynamics of viral replication in infants with vertically acquired human immunodeficiency virus type 1 infection.Journal of Clinical Investigation, 1996
- Influence of host genotype on progression to acquired immunodeficiency syndrome among children infected with human immunodeficiency virus type 1The Journal of Pediatrics, 1995
- Shortened survival in infants vertically infected with human immunodeficiency virus with elevated p24 antigenemiaThe Journal of Pediatrics, 1995
- Infant Mortality and Maternal Vitamin A Deficiency During Human Immunodeficiency Virus InfectionClinical Infectious Diseases, 1995
- Onset of clinical signs in children with HIV-1 perinatal infectionAIDS, 1995
- A population-based comparison of the clinical course of children and adults with AIDSAIDS, 1995
- Rapid Increases In Load Of Human Immunodeficiency Virus Correlate With Early Disease Progression and Loss of CD4 Cells in Vertically Infected InfantsThe Journal of Infectious Diseases, 1994